Clinical Trials
13 trialsNCT07060807 2026-06-01
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07214779 2026-06-01
MAESTRA 2
Incyte Corporation
Phase 3 Recruiting
NCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06843447 2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06312176 2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06787612 2026-05-20
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT06994195 2026-04-20
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT06072781 2026-04-02
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
NCT05281471 2026-03-18
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Phase 3 Recruiting
NCT07218809 2026-01-16
TREVI-OC-01
AstraZeneca
Phase 3 Recruiting
NCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting